{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:54:17Z","timestamp":1790146457606,"version":"4.0.1"},"reference-count":23,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2006,11,1]],"date-time":"2006-11-01T00:00:00Z","timestamp":1162339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2006,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The objective of the present study was to identify the optimal R207910-containing regimen to administer to patients who cannot receive rifampin (RIF) and isoniazid (INH) because of multidrug-resistant tuberculosis (MDR-TB), concomitant use of antiretroviral drugs, or toxicity. Mice were infected intravenously with 5 \u00d7 10\n            <jats:sup>6<\/jats:sup>\n            CFU of the H37Rv strain and treated five times per week with R207910 alone or various combinations of R207910 with the second-line drugs amikacin (AMK), pyrazinamide (PZA), moxifloxacin (MXF), and ethionamide (ETH). All R207910-containing regimens were significantly more active than the non-R207910-containing regimens after 1 month of therapy. When given for 2 months, R207910 alone was more active than the WHO standard first-line regimen RIF-INH-PZA. When R207910 was combined with second-line drugs, the combinations were more active than the currently recommended regimen of MDR-TB AMK-ETH-MXF-PZA, and culture negativity of both the lungs and spleen was reached after 2 months of treatment in almost every case.\n          <\/jats:p>","DOI":"10.1128\/aac.00766-06","type":"journal-article","created":{"date-parts":[[2006,10,25]],"date-time":"2006-10-25T20:58:50Z","timestamp":1161809930000},"page":"3543-3547","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":121,"title":["Combinations of R207910 with Drugs Used To Treat Multidrug-Resistant Tuberculosis Have the Potential To Shorten Treatment Duration"],"prefix":"10.1128","volume":"50","author":[{"given":"Nacer","family":"Lounis","sequence":"first","affiliation":[{"name":"Laboratoire de Bacte\u0301riologie, Faculte\u0301 de Me\u0301decine Pitie\u0301-Salpe\u0302trie\u0300re, and Centre National de Re\u0301fe\u0301rence de la Re\u0301sistance des Mycobacte\u0301ries aux Antituberculeux, Groupe Hospitalier Pitie\u0301-Salpe\u0302trie\u0300re, Universite\u0301 Pierre et Marie Curie Paris 6, Paris, France"},{"name":"Tibotec Pharmaceuticals Ltd., Johnson &amp; Johnson, Turnhoutseweg 30, 2340 Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Veziris","sequence":"additional","affiliation":[{"name":"Laboratoire de Bacte\u0301riologie, Faculte\u0301 de Me\u0301decine Pitie\u0301-Salpe\u0302trie\u0300re, and Centre National de Re\u0301fe\u0301rence de la Re\u0301sistance des Mycobacte\u0301ries aux Antituberculeux, Groupe Hospitalier Pitie\u0301-Salpe\u0302trie\u0300re, Universite\u0301 Pierre et Marie Curie Paris 6, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aure\u0301lie","family":"Chauffour","sequence":"additional","affiliation":[{"name":"Laboratoire de Bacte\u0301riologie, Faculte\u0301 de Me\u0301decine Pitie\u0301-Salpe\u0302trie\u0300re, and Centre National de Re\u0301fe\u0301rence de la Re\u0301sistance des Mycobacte\u0301ries aux Antituberculeux, Groupe Hospitalier Pitie\u0301-Salpe\u0302trie\u0300re, Universite\u0301 Pierre et Marie Curie Paris 6, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Truffot-Pernot","sequence":"additional","affiliation":[{"name":"Laboratoire de Bacte\u0301riologie, Faculte\u0301 de Me\u0301decine Pitie\u0301-Salpe\u0302trie\u0300re, and Centre National de Re\u0301fe\u0301rence de la Re\u0301sistance des Mycobacte\u0301ries aux Antituberculeux, Groupe Hospitalier Pitie\u0301-Salpe\u0302trie\u0300re, Universite\u0301 Pierre et Marie Curie Paris 6, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"Andries","sequence":"additional","affiliation":[{"name":"Tibotec Pharmaceuticals Ltd., Johnson &amp; Johnson, Turnhoutseweg 30, 2340 Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Jarlier","sequence":"additional","affiliation":[{"name":"Laboratoire de Bacte\u0301riologie, Faculte\u0301 de Me\u0301decine Pitie\u0301-Salpe\u0302trie\u0300re, and Centre National de Re\u0301fe\u0301rence de la Re\u0301sistance des Mycobacte\u0301ries aux Antituberculeux, Groupe Hospitalier Pitie\u0301-Salpe\u0302trie\u0300re, Universite\u0301 Pierre et Marie Curie Paris 6, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1106753"},{"key":"e_1_3_2_3_2","unstructured":"Arora S. K. N. Sinha R. Sinha and R. S. Upadhyaya. 17 Nov. 2005. U.S. patent application US 2005\/0256128 A1."},{"key":"e_1_3_2_4_2","unstructured":"Crofton J. P. Chaulet and D. Maher. 1997. Guidelines for the management of drug-resistant tuberculosis. Report WHO\/TB\/96.210. World Health Organization Geneva Switzerland."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.8.2442-2444.2003"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.1.360-362.2003"},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1164\/rccm.200305-682OC","volume":"168","year":"2003","unstructured":"Gosling, R. D., L. O. Uiso, N. E. Sam, E. Bongard, E. G. Kanduma, M. Nyindo, R. W. Morris, and S. Gillespie. 2003. The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. Am. J. Respir. Crit. Care Med.168:1342-1345.","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"e_1_3_2_8_2","unstructured":"Huitric E. K. Andries and S. E. Hoffner. 2005. MIC distribution of R207910: an in vitro study on drug-susceptible and drug-resistant Mycobacterium tuberculosis abstr. F-1477. Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology Washington D.C."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.6.1341"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.8.2066"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.4.1558-1560.2006"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00052-06"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.11.2344"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/140.5.1189"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.3.607"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.12.3482-3486.2001"},{"key":"e_1_3_2_17_2","unstructured":"Matsumoto M. Hashizume H. T. Tomishige M. Kawasaki M. Komatsu H. Tsubouchi H. Sasaki and T. Sumida. 2005. OPC-67683: a novel class anti-tuberculosis drug candidate. Symposium: new therapeutic approaches for tuberculosis. Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology Washington D.C."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200407-885OC"},{"key":"e_1_3_2_19_2","unstructured":"Nuermberger E. L. I. Rosenthal S. Tyagi K. Williams N. Lounis W. R. Bishai and J. H. Grosset. 2005. The nitroimidazopyran Pa-824 (Pa) increases the potency of the rifampin moxifloxacin pyrazinamide (RMZ)-based regimen in the murine model of tuberculosis (TB) abstr. B-737. Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology Washington D.C."},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0041-3879(91)90025-N"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.10.3117-3122.2003"},{"key":"e_1_3_2_22_2","first-page":"3091","volume":"56","year":"1998","unstructured":"Wada, M. 1998. The adverse reactions of anti-tuberculosis drugs and its management. Nippon Rinsho56:3091-3095.","journal-title":"Nippon Rinsho"},{"key":"e_1_3_2_23_2","unstructured":"World Health Organization. 1997. Treatment of tuberculosis: guidelines for national programmes 2nd ed. Report WHO\/TB\/97.220. World Health Organization Geneva Switzerland."},{"key":"e_1_3_2_24_2","first-page":"16","volume":"7","year":"2003","unstructured":"Zhang, Y., and D. Mitchison. 2003. The curious characteristics of pyrazinamide: a review. Int. J. Tuberc. Lung Dis.7:16-21.","journal-title":"Int. J. Tuberc. Lung Dis."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00766-06","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00766-06","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T18:59:39Z","timestamp":1645469979000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00766-06"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2006,11]]}},"alternative-id":["10.1128\/AAC.00766-06"],"URL":"https:\/\/doi.org\/10.1128\/aac.00766-06","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,11]]},"assertion":[{"value":"2006-06-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2006-08-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2006-11-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}